ReviewAnti-inflammatory & anti-allergy agents in medicinal chemistry2026
Anti-inflammatory Potential of
Review in Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pongamia pinnata (L.) has long been used in both the Ayurvedic and Siddha systems of medicine. It belongs to the leguminous family and shows significant potential for antiinflammatory activity, further supported by growing pharmacological and mechanistic evidence. This paper discusses recent advances in the study of its phytochemistry and the molecular mechanisms underlying its anti-inflammatory effects. Flavonoids, furanoflavonoids, terpenoids, and sterols are the main bioactive compounds, which modulate key inflammatory pathways such as NF- κB, COX-2, iNOS, and the expression of proinflammatory cytokines. Antioxidant, immunomodulatory, and membrane-stabilising activities help reduce oxidative stress and inflammation. Diseasespecific evidence highlights potential roles in arthritis, metabolic inflammation, neurodegeneration, and skin disorders. Emerging formulation approaches, including nanoparticles, ethosomes, and hydrogels, have improved the bioavailability, stability, and targeted delivery of various constituents of P. pinnata. Although preclinical studies have demonstrated a favourable safety profile, inadequate clinical validation and the need for standardised formulations remain two major barriers to therapeutic translation. This review aims to guide future research towards standardisation, pharmacokinetics, and formulation development to position P. pinnata as an attractive candidate for anti-inflammatory drug development.
Indexed as
Identifiers
41941307What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.